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ABSTRACT

The purpose of this pilot study was to determine the feasibility of conducting a
full study comparing the differential effects of pre-treatment with atracurium, pre
treatment with lidocaine, and pre-treatment with atracurium and lidocaine on the severity
of fasciculations in patients who received succinylcholine. The research question under
examination was: will there be any difference in the observed severity of fasciculation in
subjects receiving succinylcholine who also receive one of three pharmacological
regimens consisting of either lidocaine, atracurium, or lidocaine and atracurium in
combination?
Since the date that d-tubocuraine became commercially unavailable, no
alternative pharmaceutical agent has been identified in the published literature as an
optimal medication, either by dose or regimen, to prevent the occurrence or decrease the
severity of fasciculations, following the administration of the depolarizing muscle
relaxant succinylcholine. Muscle fasciculations have been associated with myalgia, as
well as increases in intragastric, intracranial, and intraocular pressure. The bulk of
investigation in this area, to date, has focused on the use of the non-depolarizing muscle
relaxants rocuronium and atracurium. These muscle relaxants have been used alone and
in combination with the local anesthetic, lidocaine, as a pretreatment prior to the
administration of succinylcholine. All three of these medications (rocuronium,
atracurium, and lidocaine) have demonstrated effectiveness at decreasing fasciculations
when administered alone and in combination. No specific dosing schema, however, has
been universally demonstrated to be most effective in decreasing or eliminating
fasciculations in association with succinylcholine use.
vii

The study was a randomized, double blinded, quasi-experimental research design.
The researcher approached subjects from the daily operating room schedule at a 600-bed
Level I Trauma Center in the Southeastern United States who met all inclusion criteria
and no exclusion criteria for participation. The population studied was limited to patients
undergoing laparoscopic surgery, with an ASA physical status of I or II, between the ages
of 18-50, with a BMI between 18-30. The measurement instrument selected to measure
fasciculation was a four-point scale called the Observers Assessment of Fasciculation
Scale.
Results of this pilot study showed that 1.5mg/kg of lidocaine was able to prevent
fasciculations in 75% of subjects, 0.05mg/kg of atracurium to prevent fasciculations in
40% of patients, and their combination to prevent fasciculation in 60% of subjects.
However, all three groups were effective at limiting observed fasciculations to a score of
1 on the instrument utilized. It is recommended that this study should be replicated
utilizing a larger population because the relative ease of subject access and the
considerable degree of clinical significance found as a result of the conduction of the
study. Further more, it appears that this pilot study allowed only for the possibility that
smokers may be more likely to fasciculate than non-smokers, regardless of any of the
pretreatment regimens used for this pilot study. This finding should be investigated in
great depth in future studies.
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CHAPTER I
Introduction
It is well documented that the administration of succinylcholine (SCh) causes
muscle fasciculations, which may lead to untoward problems, including severe
postoperative muscle soreness (Wong & Chung, 2000). As a result, it is acceptable
standard anesthetic practice to aim to decrease the likelihood of fasciculations when
administering SCh during the administration of general anesthesia.
Historically, many methods for prevention of fasciculations have been employed.
These have included pretreatment with any of the following medications: Dantrolene,
calcium gluconate, lidocaine, phenytoin, ascorbic acid, magnesium sulfate, acetylsalicylic
acid, non-steroidal anti-inflammatory agents, chlorpromazine, diazepam, midazolam, or
subtherapuetic doses of nondepolarizing neuromuscular blockade, such as atracurium
(0.05 mg/kg). In addition to all of these pharmacologic interventions, high doses of
lidocaine (1.5-3 mg/kg) have been shown to be effective in reducing fasciculations and
post-operative myalgias secondary to the use of SCh (Raman & San, 1997). All of these
modalities have not, however, been consistently reliable in their ability to prevent
fasciculation
Purpose of the Study

The purpose of this pilot study was to examine and compare the efficacy of
pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as
they relate to the incidence and severity of fasciculation in subjects receiving
succinylcholine. A second purpose was to determine the feasibility of conducting a full
scale research study to compare the differential effects of pretreatment with lidocaine,
I

atracurium, or lidocaine and atracurium in combination as they relate to the incidence and
severity of fasciculation in subjects receiving succinylcholine. A third purpose was to
identify correlations between demographic data and fasciculation in subjects who
received lidocaine, atracurium, or lidocaine and atracurium in combination as they relate
to the incidence and severity of fasciculation in subjects receiving succinylcholine.
The research question asked: Will there be any difference in the observed severity
of fasciculation in subjects receiving SCh who also receive one of three pharmacological
regimens consisting of either lidocaine, atracurium, or lidocaine and atracurium in
combination?
Research Hypothesis and Physiological Framework
The null hypothesis for this study states that there will be no difference in the
observed severity of fasciculations in surgical patients who receive SCh who are
pretreated with one of three pharmacological regimens consisting of either lidocaine,
atracurium, or lidocaine and atracurium in combination. The framework that guided this
research study was based on the currently accepted evidence that the neurotransmitter
acetylcholine (ACh) acts on both the postjunctional cholinoceptors as well as the
prejunctional cholinoceptors to mobilize ACh from reserves in prejunctional sites in
quantity sufficient to keep up with the demand from stimulation (Bowman, 1980).
Succinylcholine is the most commonly used depolarizing muscle relaxant in the
United States. When administered, SCh binds to and activates the same receptors as does
the neurotransmitter ACh. When ACh receptors are stimulated, rapid muscle relaxation
or paralysis occurs by desynchronized depolarization of the muscle member
(sarcolemmea), which results in disorganized muscle contractions, which are called
2

fasciculations. These disorganized muscle contractions lead to a period of muscle
relaxation called a refractory period. One way SCh differs from ACh is that the former is
not metabolized by acetylchoinesterase in the synaptic cleft. Instead, SCh is hydrolyzed
by cholinesterase in the plasma. Depending on the quantity and quality of an individual's
plasma cholinesterase, SCh remains available to bind repeatedly with the ACh receptors
(Lien & Savarese, 2000). The suppression of SCh-induced fasciculations results from the
ability of nondepolarizing drugs, such as tubocurarine, to act on prejunctional receptors to
prevent repetitive discharging of motor nerve terminals (Hartman, Fiamengo, & Riker,
1986).
The potential benefits to the subjects of this study, and any subsequent full study,
include a more comfortable recovery time void of additional post-operative discomfort
from SCh-induced myalgias, prevention of muscle cell breakdown that leads to
myoglobinuria that has been demonstrated to result in renal failure in some susceptible
individuals, fewer returns to the emergency room for discomfort related to fasciculation,
and the potential for a decreased need for post-operative pain medication secondary to
cellular damage related to fasciculation. Preventing these sequale related to fasciculation
could potentially allow subjects to return earlier to their preoperative baseline status.
All future pat!ents who undergo surgery and receive SCh could be potential
benefactors from the findings of this study. If this study demonstrates that lidocaine,
atracurium, or a combination of both lidocaine and atracurium administered prior to SCh
has a superior ability to diminish or prevent fasciculations, future surgical patients may
experience fewer side effects of fasciculations related to SCh administration.
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CHAPTER II

Review of literature
When rapid control of the airway is required, such as would be the case in patients
with full stomachs, parturients, trauma victims, and individuals with existing active reflux
disease, SCh is the fastest acting muscle relaxant used to facilitate endotracheal
intubation. Currently, SCh is the only depolarizing muscle relaxant in use in the United
States. Succinylcholine exerts its effects by minimizing the action of ACh on cholinergic
receptors, resulting in protracted depolarization of the postjunctional membrane
following administration of an intravenous dose of SCh. Ion channels in the myoneural
membrane remain open for an extended period of time due to the slow hydrolysis of SCh.
This delay of breakdown, and the elimination properties of SCh, prevent repolarization
and so inhibit further muscular depolarization response despite succeeding release of
ACh from the neuronal �nd plate (Stoelting, 1999). The phannocodynamics of SCh allow
for rapid onset (30-60 seconds) and short duration of action of 3-5 minutes (Stoelting,
1999).
Despite these desirable properties, SCh has several routine adverse effects that
can limit its use. These include cardiac dysrythmias, hyperkalemia, myalgia,
myoglobinuria, increased intragastric pressure, increased intraocular pressure, increased
intracranial pressure, sustained skeletal muscle contractions or fasciculations (Stoelting,
1999), and elevation of serum creatine kinase and potassium (Cannon, 1994). The
literature has reported the occurrence of fasciculations following SCh administration to •
be associated with all of these undesirable effects.
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Standaert (1994) defined fasciculations as the simultaneous contraction of the
multitude of muscle cells in a single motor unit. Succinylcholine acts like ACh to
depolarize the prejunctional receptors in the neuromuscular junction, but differs from
ACh in the fact that the depolarization caused by SCh is sustained. This characteristic is
related to the chemical properties of SCh, which significantly slows its breakdown in
VIVO.

In a review article, Bowman (1980) described the classical view of neuromuscular
transmission. He stated that nerve impulses cause the release of ACh from the terminal
nerve endings. The released ACh then acts on the cholinergic receptors located on the
motor end plate in the postjunctional membrane. It is at this final receptor that
neurotransmitter coupling occurs, which leads to depolarization and muscle contraction.
Other investigators have challenged this point of view over the years. In 1970, Blaber
showed that ACh also works prejunctionally to mobilize additional transmitter reserves.
He demonstrated this activity with decamethonium, a drug that acts similarly to ACh on
the motor end plate. By using Tubocurarine, a nondepolarizing muscle relaxant, which is
known to work on prejunctioninal receptors, Blaber (1970) was able to block the effects
of decamethonium, thereby demonstrating prejunctional involvement. Kitamura,
Yoshiya, Tashiro, and Negishi, in their 1981 study, injected 35 rabbits with neurotoxins
that work specifically on prejunctional receptors. Their findings suggested the possible
action of SCh on the prejunctional site. Therefore, the mechanism to suppress SCh
induced fasciculation was postulated to be through the blockage of the prejunctioninal
receptors.
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The physiology of muscle fasciculations associated with the use of SCh is well
understood. The basis of scientific understanding of SCh has been attributed to the
effects of this agent on the prejunctional site, which, when stimulated, results in the
individual asynchronous depolarization of muscle cells, causing generalized
uncoordinated muscle contractions (Hartman, Fiamengo, Walter, & Riker, 1986).
Muscle hyper-excitability from SCh can be reflected by myotonia and hyperkalemia, and
this effect can be credited to up-regulation of ACh recept�rs (Haeseler et al., 2000).
Haeseler et al. looked at the active metabolite of SCh, succinic acid, as a possible cause
of fasciculations. Using human skeletal muscle sodium channels expressed in human
embryonic kidney cells, these authors found that succinic acid had similar affects on
voltage-dependent activation as does low calcium levels, which could lead to nerve and
muscle cell excitability and spastic skeletal muscle contractions.
Many authorities are investigating ways to prevent the occurrence of
fasciculations after the administration of SCh with the intent of curtailing the occurrence
of skeletal fasciculations which result from SCh administration (Cannon, 1994).
Investigators have examined this phenomenon from a variety of angles and have utilized
a multitude of different pharmacologic agents during their investigations for an optimal
treatment to prevent fasciculations. These include benzodiazepines, nondepolarizing
muscle relaxants (NDMR), and the local anesthetic, lidocaine. However, the current
literature fails to support any one intervention as the best treatment. To date, the use of
NDMR to prevent or decrease fasciculation remains the focus of most investigators as
nondepolarizing muscle relaxants have been shown to most effectively decrease muscle
fasciculations following the administration of SCh.
7

Erkola, Salmenpera, and Tammisto (1980) compared diazepam and tubocurarine
(dTc) 0.05mg/kg as a pretreatment to prevent fasciculations. Sixty-one subjects were
randomly placed into one of three groups, a diazepam group, tubocurarine group, and a
control group utilizing saline. The researchers found that dTc decreased the severity and
frequency of fasciculations, where the diazepam failed to do so compared to the control
group. They also measured potassium levels after SCh and found these measurements to
be lower in the dTc group than in the diazepam group.
In the 1990 issue of the British publication Anaesthesia, Mingus, Herlich, &
Eisenkraft detailed their double-blinded, randomized study comparing two NDMRs with
midazolam to determine which agent would best attenuate fasciculations among 80
female patients who underwent laproscopic surgery. Again, the subjects in the
benzodiazepine group had a greater incidence of fasciculations than did the subjects in
the NDMR groups.
Another study with midazolam was carried out to see if the occurrence of
fasciculations could be diminished with benzodiazepine pretreatment. In their 1993 study,
Quentin, Fisher, & Matjasko found no significant decrease in the frequency of
fasciculations when midazolam was administered, as compared to normal saline when
administered to 69 female patients who underwent diagnostic laparoscopies or tubal
ligations.
In 1995, Stacey, Barclay, Asai, & Vaughan were unable to evidence a decrease in
potassium levels in subjects who received intravenous magnesium before a depolarizing
muscle relaxant dosage was administered. These authors did find in randomized groups,
however, that fasciculations occurred less often when magnesium was administered prior
8

to rapid sequence intubation utilizing SCh to facilitate endotracheal intubation. The
decrease in fasciculations was attributed to magnesium's ability to inhibit the release of
A Ch and thereby diminish the occurrence of fasciculation.
Multiple investigators have attempted to decrease SCh-induced fasciculations by
administering either small doses of SCh or a NDMR as pretreatment (Osullivan,
Williams, & Calvey, 1988; Koenig, 1992; Blanc, Vaillancourt, & Brisson, 1986; Harvey,
Roland, Bailey, Tomlin, & Williams, 1998). The pretreatment doses of SCh and elapsed
time prior to induction varied as follows: 10mg and 45seconds, O. l mg/kg and 60seconds,
0. l mg/kg and 60seconds, and 0.3mg/kg and 2 10 seconds. All studies, with the exception
of one (Koenig, 1992), found SCh to be less effective in attenuating fasciculations when
compared to NDMR. The group size varied respectively as follows: 15 subjects/group,
19/20 subjects per group, 16 subjects/group, and 20 subjects/group. Osullivan, Williams,
& Calvery used _60 ASA Physical Status-I females ages 19-66 for elective plastic, ENT,
and gynecological surgeries. Harvey, Roland Bailey, Tomlin, & Williams studied 101
ASA Physical Status I and II subjects ages 18-65 without regard to type of surgery.
Koenig used 45 adult head trauma patients presenting to the emergency room who
. required intubation and Blanc, Vaillancourt, & Brisson utilized children ages two-nine
classified as meeting ASA Physical Status-I requirements. Interpretation of the results
may differ since the doses and time frame before inductions also varied.
Some of the nondepolarizing muscle relaxants that have been studied as a pre
. treatment to attenuate SCh-induced fasciculations include pancuronium, vecuronium,
. atracurium, tubocurarine, rocuronium, cis-atracurium, and gallamine. There have been
multiple documented studies comparing many types of NDMR as possible treatments to
9

prevent fasciculation. Researchers have attempted to discern optimal dosages of
medications, as well as the ideal timing of their administration. To date, no conclusive
findings have been published that identify the optimal treatment or specific agent for
attenuating succinylcholine-induced fasiciculations.
The traditional view regarding the pharmacodynamics of NDMR, such as
tubocurarine on neuromuscular transmission, holds that such drugs work on the
postjunctional receptors by blocking Ach; thereby preventing neuromuscular
transmission (Wong & Chung, 2000). It is generally accepted that different NDMRs
work on different parts of the neuromuscular junction. This belief supports the
observations of why pretreatment with different NDMRs have different incidences of
fasciculation. After completing their study, Osullivan, Williams, & Calvey (1 988)
suggested that a NDMR may modify fasciculations by inhibiting prejunctional
depolarization leading to decreased rate of motor unit firing. Bowmans work in 1 980
also suggested that NDMRs act on both presynaptic and postsynaptic receptors.
All NDMRs have a different speed of onset, which is a characteristic of their
individual chemical properties. Therefore, it is a logical reasoning that the speed of onset
of a specific drug may affect how well the drug works to prevent fasciculations. In
addition, the time interval between the administration of the NDMR and the
administration of SCh influences the NDMRs ability to prevent fasciculations. Pinchak,
Smith, Shepard, & Patterson conducted a study in1 994 that compared the incidence of
fasciculations when pancuronium 1 mg, atracurium 5mg, tubocurarine 3mg, and
vecuroniumlmg were administered at different time intervals prior to SCh
administration. A potential source of weakness in this pilot study was that the sample
10

sizes among their different groups were not equal. However, the exact numbers of
subjects in any one group was small, which limits how generalizable the findings are.
Intervals of 0- 1, 1-2, 2-3, 3-4, and 4-5 minutes were compared. Waiting time response
curves were calculated from the gathered data. Confidence intervals were set at 95%.
Results demonstrated the incidence of observed fasciculations decreased with increasing
waiting time for each NDMR tested. The probability of preventing fasciculation 80-90%
of the time occurred when tubocurarine was given either two minutes and 46 seconds or
three minutes and two seconds before SCh administration, and when atracurium was
. given two minutes and 16 seconds or three minutes and 24 seconds prior to the
administration of SCh. These results could be explained based in part on the drug's
potency.
In a 1992 study by Law Min, Bekavac, Glavinovic, Donati, & Bevan, frog muscle
in vitro was utilized to show that the speed of onset of the NDMRs under investigation
was inversely proportional to each drugs potency. These authors related their findings to
the accepted belief that less repetitive binding occurs on ACh receptors in association
with less potent NDMR. The concept of diminished binding characteristic of less potent
NDMRs is now widely accepted. Contrasting these findings, Motamed, Choquette &
Donati, (1 997) used equipotent doses of rocuronium in 42 pa�ients and administered the
doses at 1.5 and three minutes respectively. However, even though the three-minute
group had fewer fasciculations, the difference was statistically insignificant.
The current literature regarding defasciculating doses ofNDMRs appears to be
focused on the use of rocuronium and atracurium. Some of the many authors that have
yielded significant contributions to the current body of knowledge regarding the use of
11

rocuronium and atracurium include: Tsui, Reid, Gupta, Kearney, Mayson, & Finucane,
(1998); Demers-Pelletier, Drolet, Girard, & Donatie, (1 997); Martin, Carrier, Pirlet,
Claprood, & Tetrault, (1998); Pinchak, Smith, Shepard, & Patterson, (1 994); Raman &
San, (1997); Harvey, Roland, Bailey, Tomlin, & Williams (1998); Kim, Cho, Lee, Lim,
Chang, & Yoon ( 1999). Those who have explored this subject have not universally
agreed upon the dosage ofrocuronium that works best as a defasciculator. Neither have
they been able to reach a consensus regarding the optimal time from administration of
NDMR and SCh to fasciculation, nor the dose of SCh that is associated with the greatest
degree of fasciculation. Dosages of rocuronium that have been evaluated in studies
investigating the inhibition of fasciculation include 0.03mg/kg 0.05mg/kg, 0.06mg/kg,
and 0. l mg/kg. Time elapsed between the defasciculating doses of NDMR and the
administration of SCh also have varied by 2.5 minutes (with a range of l .5min., 3min.,
and 4minutes). Dosage of SCh has been fairly standard and consistent at 1 .5mg and 2mg.
Demers-Pelletier, Drolet, Girard, & Donati (1 997) and Motamed, Choquette, & Donati,
(1 997) both used similar sample sizes and looked at 0.05mg/kg of rocuronium with a 1 .5minute interval. Results of these studies demonstrated that 52% and 70% of subjects
respectively did not fasciculate when pre-treated with 0.05mg/kg of rocuronium.
Motamed et al., examined rocuronium administered at 0.05mg/kg followed at three
minutes by SCh and found 90% of the subjects did not fasciculate. Since different scales
were used to judge the intensity of the fasciculations that occurred, however, it was not
possible to make an adequate comparison of these findings between these studies.
Martin, Carrier, Pirlet, Claprood, & Tetrault (1 998) and Mencke, Schreiber,
Becker, Bolte, & Fuchs-Buder (2002) used rocuronium at a dose of 0.06mg/kg and
12

allowed a four-minute interval to elapse prior to SCh administration. Both of these
studies revealed 85% and 80% of 20 and 40 subjects respectively did not exhibit evidence
of fasciculations. A defasciculating dose of 0.6mg/kg of rocuronium is equal to 1 0% of
the intubation dosage of rocuronium when the intubation dose is twice the published
effective dose of 95% of the population. In contrast, a study published in the October
2002 issue of the Journal of the American Association ofNurse Anesthetists, by Spence,
Domen-Herbert, Boulette, Olson and Maye found 0.03mg/kg of rocuronium to be
effective in preventing fasciculations in 70% of subjects with a three-minute interval
between the time of administration of the pretreatment (atracurium) and administration of
SCh. Disagreement in the literature, from this author's review, appears to be the only
consistency in regard to this subject matter.
According to Stoelting ( 1 999); the lack of potency of rocuronium is considered to
play a key factor in its rapid onset and effectiveness as a defasciculator. These
observations result from a greater number of molecules being available in the
neuromuscular junctions. Eighty-five percent of the subjects studied by Martin, Carrier,
Pirlet, Claprood, & Tetrault (1998) who received 0.06mg/kg (10% of intubating dose) of
rocuronium did not show evidence of fasciculations. In the same study, the authors
reported using 0.02mg/kg (<10% of the intubating dose) of atracurium, 0.0l mg/kg ( 1 0%
of the intubating dose) of vecuronium, 0.06mg/kg {>10% of the intubating dose) of
mivacurium, and 0.05mg/kg (10% of the intubating dose) of tubocurarine for comparison.
All of the NDMRs reduced fasciculations, but to a lesser extent than rocuronium. A four
minute time interval between NDMR administration and the administration ofSCh was
utilized. Given the larger dose of rocuronium used, and the longer time interval before the
13

administration of SCh, it is surprising that a greater percentage of subjects failed to show
evidence of fasciculations than was observed.
In a study performed by Mencke, Schreiber, Becker, Bolte, & Fuchs-Buder in
2002, 80% of the subjects who received rocuronium had a reduction in severity and
incidence of fasciculations as opposed to 2.5% in the control group. The authors did not
delineate an ordinal breakdown of fasciculation severity as other authors had done. The
ability for rocuronium 0.05mg/kg and vecuronium 0.007mg/kg (a smaller dose then in
other studies) to defasciculate were compared after a time interval of three minutes in two
equal sized samples. Again, rocuronium was superior with 85% of subjects inhibited
from fasciculating in contrast to 50% of the vecuronium group subjects experiencin�
fasciculation (Kim, Cho, Lee, Lim, Chang, & Yoon, 1999).
In another study with smaller subject groups comparing.rocuronium with
atracurium (an intermediate acting NDMR), higher doses of both drugs were used. This
study utilized O. l mg/kg of both drugs with, 1 .5-minute time intervals between their
administration and the administration of SCh. This study found rocuronium to be four
times more effective at reducing fasciculations (78% versus 21 % reduction) in
comparison to atracurium (Tsui, Reid, Gupta, Kearney, Mayson, & Finucane, 1 998).
Atracurium, an intermediate acting NDMR, has been found to be an effective
treatment to reduce fasciculations when SCh is administered. Atracurium works by
blocking both the presynaptic and postsynaptic receptors of the neuromuscular junction
(Hughes & Pa�e, 1983). In a study comparing atracurium to tubocurarine, atracurium at
a dose of 0.025mg/kg was found to be effective at reducing fasciculation, but less so than
0.05 mg/kg of tubocurarine (Sosis, Broad, Larijani, & Marr, 1987). More recent studies
14

have used higher doses of atracurium, (0.05mg/kg) in an attempt to prevent fasciculation.
In 1996, Hochhalter, compared 0.05mg/kg of atracurium with a control group receiving
normal saline. The time interval between administration and fasciculation was three
minutes. Hochhalter found atracurium to be effective with 73% of the subjects failing to
exhibit any measured fasciculations (n=24). Raman & San (1997) compared subjects
receiving 0.05 mg/kg of atracurium in combination with 1.5 mg/kg of lidocaine,
0.05mg/kg of atracurium without lidocaine, l .5mg/kg of lidocaine without atracurium,
and a control group receiving none of these drugs. Study results indicated atracurium in
combination with lidocaine was more effective than atracurium alone. Seventy percent of
subjects receiving atracurium in combination with lidocaine showed no signs of
fasciculation, while" only 60% of the subjects who received atracurium demonstrated
absence of fasciculation. All subjects received their pretreatment three minutes before
SCh was administered.
Higher doses of atracurium were utilized in a study by Tsui, Reid, Gupta,
Kearney, Mayson, & Finucane (1998). These authors used a dose of atracurium 0.lmg/kg
along with a shorter (1.5-minute) interval between atracurium administration and the
subsequent SCh administration. In this study, 79% of subjects failed to have
fasciculation inhibited. The difference between the ti.me intervals of 1 .5 minutes versu� 3
minutes, made more difference than the drug dosage, and was most likely responsible for
the greater observed difference. It should be noted that in both studies by Hochhalter
(1996) and Raman & San (1997), using 0.05mg/kg of atracurium with a three minute
interval of elapsed time prior to SCh proved to be effective in reducing fasciculations.
Martin, Carrier, Pirlet, Claprood, & Tetrault (1998) utilized a four minute waiting period
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between the administration of atracurium 0.02mg/kg, rocuronium 0.06mg/ kg, 0.01
mg/kg, or mivacurium 0.02mg/kg and SCh administration. Sixty-five percent of the
subjects receiving atracurium did not fasciculate. This is in contrast to fasciculation
inhibition of 85% in the rocuronium group. Although the four-minute time interval used
by Martin et al. should have been long enough for both of these NDMRs to adequately
block the prejunctional receptors, the study findings did not support this supposition. This
author postulates that perhaps the lower dose of atracurium (0.02mg/kg ) that Martin et
·a l. used in their study accounted for the difference in the incidence of fasciculations in
these study subjects.
The efficacy of the local anesthetic lidocaine to reduce fasciculations and
associated myalgias has been compared to the efficacy of NDMRs to reduce the same.
Lidocaine is thought to be effective because it has membrane-stabilizing effects
(Winkinski, Usubiaga, Usubiaga, & Wikinski, 1965). Naguib, Farag, & Magbagbeola
(1988) observed fasciculations in 10 subjects given l mg/kg of lidocaine. The intensity of
fasciculations in the study' s subjects was comparable to those observed in the control
group. Study results, therefore, did not support the idea that lidocaine would be effective
in preventing fasciculation in association with SCh administration.
Lidocaine has also been compared with rocuronium in the search for the most
effective and least problematic agent to utilize for fasciculation inhibition. Seventy-nine
percent of subjects receiving 1.5 mg/kg of lidocaine, compared to 29% of subjects
receiving 0.03mg/kg of rocuronium, showed signs of fasciculations in results reported by
Spence, Domen-Herbert, Boulette, Olson, Vacchiano, & Maye in 2002.
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Conversely, in their 1997 study of fasciculations following SCh administration,
Raman and San observed that 85% of subjects in their lidocaine group showed signs of
fasciculation. In their study Raman and San also examined the administration of
atracurium and a combination of lidocaine and atracurium and found that the combination
decreased the incidence of fasciculations more so then either drug administered alone.
Sixty percent of the subjects in the atracurium group did not fasciculate when SCh was
subsequently administered. All groups contained 20 subjects.
A third study using a large sample of 395 randomly assigned subjects by Melnick,
Chalasani, Lim Uy, Phitayakom, Mallett, & Rudy compared l .5mg/kg of lidocaine,
0.06mg/kg tubocurarine, or a combination of both l .5mg/kg of lidocaine and 0.06mg/kg
oftubocurarine to a control group who only received normal saline (1 987). The subjects
in the tubocurarine groups had a lower incidence of fasciculations when compared the
subje�ts in both the saline and lidocaine groups. Lidocaine was not found to decrease
fasciculation when compared to the control group in this study. The com�ination of
lidocaine with tubocurarine, however, was found to decrease both the incidence and
severity of fasciculations greater than any agent either alone or in combination.
Nondepolarizing muscle relaxants attenuate fasciculation by their action on the
prejunctional cholinergic receptors. To date, the bulk of research on the attenuation of
fasciculations with SCh use has focused on the use of atracurium and rocuronium prior to
depolarizing muscle relaxant administration. No consensus, however, is to be found in
the body of literature regarding the optimal dosages or time jnterval between the NDMR
pretreatment, the most effective dose ofNDMR, or the most effective dose of SCh
administered. Of the studies examined for this review it was found that (1) The dosages
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of NDMR that seemed to be most efficacious for diminishing fasciculations related to
SCh administration were those doses which were approximately 10% of the intubating
dose of the same agent. For atracurium the dosage would be 0.05mg/kg, whereas for
rocuronium the dosage would be 0.06mg/kg. (2) The most efficacious time interval,
which appeared to be most effective in preventing fasciculation, was at least three
minutes between the administration of the nondepolarizing dose and the intubating dose
of SCh. (3) Lidocaine given alone, in the published literature, has been shown to be
ineffective at decreasing the incidence of fasciculations in association with SCh
administration.
Flaws in study design and sampling where lidocaine has been investigated,
however, diminish the generalizability and, thus the value of these findings. In
combination with nondepolarizing muscle relaxants, lidocaine has been shown by some
researchers to enhance the effects of NDMRs ability to attenuate fasciculation compared
to either agent given alone. Therefore, this pilot study served to determine whether or not
it was feasible to seek to determine the most effective utilization of atracurium,
atracurium and lidocaine, and lidocaine for the inhibition of muscular fasciculation in
patient's receiving SCh, as measured by the Observers Assessment of Fasciculation
Scale.
In summation, it is the currently accepted scientific belief that prejunctional
cholinergic receptors, when stimulated by SChs, are responsible for causing muscular
fasciculations secondary to propagated neuronal impulses. Pretreatment with higher dose
nondepolarizing muscle relaxants administered at longer time intervals prior to SCh
administration has been shown to be the most effective treatment in preventing
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fasciculations. The practice of utilizing higher doses of NDMRs and waiting longer
intervals between the administration of the NDMR and SCh, while effective in
decreasing fasciculations, has inherent risks to patients. These risks include higher
potential of passive gastric reflux leading to aspiration, hypoxia, and hemodynamic
instability related to the induction and maintenance of general anesthesia in the absence
of any appreciable sympathetic nervous system stimulation. Continued investigation for
the most effective, but least problematic agent, or combination of agents, to prevent
fasciculation is therefore warranted and necessary.
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CHAPTER III

Methodology
Introduction

The primary purpose of this study was to examine and compare the efficacy of
pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as
they relate to the incidence and severity of fasciculation in subjects receiving
succinylcholine. A second purpose was to determine the feasibility of conducting a full
study to compare the differential effects of pretreatment with lidocaine, atracurium, or
lidocaine and atracurium in combination as they relate to the incidence and severity of
fasciculation in subjects receiving succinylcholine. The third purpose of this study was to
identify correlations between demographic data and fasciculation in subjects who
lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the
incidence and severity of fasciculation in subjects receiving succinylcholine, such as the
relationship between smoking and the occurrence of fasciculations, as well as differences
between gender and fasciculations that could hold clinical significance. The Observers
Assessment of Fasciculation Scale (OAFS) was the instrument used to measure the
severity of fasciculations. The OAFS is a four-point ordinal tool that ranks observed
muscular fasciculations on a scale of 0-3 based on their occurrence and severity.
The first section of this chapter explores the research design of this pilot study
instrument. The remainder of this chapter will present the research design as it relates to
subject sample and setting, operational and theoretical definitions, assumptions, inclusion
and exclusion criteria, study limitations, instrumentation, data analysis, study protocol,
and instrumentation, which will be utilized as the foundation of this clinical investigation.
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Protection of human subject's rights considerations will be presented at the conclusion of
this chapter.
Research Design
Subjects recruited for participation in this study were identified and selected by
means of convenience sampling of all patients who are listed on the daily surgical
schedule at the research site. All subjects studied met the inclusion criteria and were void
of any exclusion criteria. This study was a prospective, double-blinded, randomized study
of 15 ASA Physical Status I and II subjects.
Subjects were randomly assigned to one of three groups. Group one was pre
treated with atracurium 0.05mg/kg IV prior to administration of l .5mg/kg IV of SCh.
Group two received l .5mg/kg IV of lidocaine prior to l .5mg/kg of SCh. Group three
received both pretreatment agents at the above-indicated doses. No control group was
utilized, since fasciculations are a normal expectation with SCh administration and
withholding intervention was considered to be an unethical practice by this author. The
specific details of the protocol are detailed later in this chapter.
Pretreatment medications in all three groups were administered to subj ects using a
double-blind format. The surgery pharmacy randomly assigned subjects to one of the
three study groups by means of computerized random selection. Syringes of study
medications were labeled with numbers (from 1- 15) by the pharmacy staff for each
subject enrolled in the study. The only study participants who knew which patient
received which study medication prior to the completion of the study was the operating
room pharmacy staff. The pharmacy staff disclosed this information when all data had
been collected and when the study was completed and the project was closed since no
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problem arose that required the investigator's or other providers ' knowledge of this
information prior to the study' s completion. Every syringe contained the same volume
amount, however, the content of the syringe varied depending on which investigational
group the subject is assigned. Dosages of all medications were calculated based on body
weight (in kilograms) by the pharmacy prior to anesthetic administration. At the end of
the study, the drugs were identified to conclude whether there was a significant difference
between the pre-treatment groups with respect to comparison of o:ne another. One
independent observer had to be utilized to judge fasciculations by the application of the
OAFS. These data were to be analyzed after the completion of the study by the statistical
computer program SPSS.
All subjectswere assigned a number once enrolled in the study. Subjects were
sequentially numbered 1 - f5 . A demographic data sheet served as the master subject list
and was maintained on all subj ects who agree to participate in the study and who had
signed the informed consent. This data sheet can be found in Appendix B and contained
the following information:
1 . Name
2. Phone Number (Contact information was collected because a secondary
researcher was following up on the patient for a separate study looking at
postoperative myalgia. )
3 . Subj ect number ( 1 - 1 00)
4. Physical Status classification
5 . Weight in Kg
6. Height in centimeters
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7. Gender
8. Smoking history
9. Pre-operative narcotic and NASID use (dose and duration)
10. Post-operative narcotic and NASID use (dose and duration)
Subjects were recruited by convince sampling. All individuals appearing on the
daily operating room schedule who met study criteria had the opportunity to participate in
this study. Subjects classified by the American Society of Anesthesiologists physical
status classification I (ASA-I), or physical status classification II (ASA-II), who were
between the ages of 18-50, and who were scheduled for elective outpatient laproscopic
surgery under general endotracheal anesthesia were approached to determine eligibility to
participate in the study. Those subjects identified by the investigator as meeting inclusion
and exclusion criteria were asked to participate. The entire investigation took place in the
surgical suites of a Level I adult and pediatric trauma center in the Southeast United
States.
Operational and Theoretical Definitions

1 . Nondepolarizing Muscle Relaxant (NDMR}- Are neuromuscular relaxing agents
that antagonize the neurotransmitter acetylcholine from reaching the acetylcholine
receptors, preventing depolarization of skeletal muscle cells and muscle
contraction.
2. American Society of Anesthesiologists (ASA}- The American Society of
Anesthesiologists is an educational, research and scientific association of
physicians organized to raise and maintain the standards of the medical practice of
anesthesiology and improve the care of the patient.
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3. ASA physical status I and II- Describes the physical status of a patient at the time
of surgery. See Appendix B for specific definitions.
4. Defasciculation- The prevention of simultaneous contraction of skeletal muscle.
5. Fasciculations- Fasciculations are the simultaneous contraction of the multitude of
muscle cells in a single motor unit (Standaert, 1994). These can be observed in all
skeletal muscles in the human body. Skeletal fasciculation are most easily
observed in the fingers, eyes, and limbs.
6. Endotracheal Anesthesia- General anesthesia that is delivered to the lungs through
the trachea via an endotracheal tube.
7. Endotracheal Tube- A large catheter that is inserted through the nose or mouth,
into the trachea, by which oxygen and volatile anesthetics are delivered.
8. Laparoscopic Surgery- Intra-abdominal surgery performed through small
incisions with the use of laparoscopic instruments. These are surgical instruments
that include a camera which transmits the image from inside the abdominal cavity
that the surgeon uses to guide the surgical procedure.
9. Neuromuscular Junction- The area between the ends of myelinated nerve fibers
and skeletal muscle.
10. Outpatient- A non-hospi�alized patient who receives same day medical treatment.
Assumptions

The basic assumptions made regarding this study were as follows:
1 . Although the validity and reliability of the OAFS is essentially unproven, for the
purpose of the current study, it was assumed that the OAFS was a reliable,
predicative, and accurate tool for measuring fasciculations.
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2. Observed fasciculations by the independent observer was consistent for all
subjects.
3. The population sample would be random.
Inclusion Criteria

1. 18-50 years of age
2. Subjects requiring elective outpatient laproscopic surgery under general
endotracheal anesthesia
3. Body Mass Index (BMI) between 18-30
4. ASA Physical Status I or II
5. Ambulatory patients only
Exclusion Criteria

1. Those patients not meeting the inclusion criteria as detailed.
2. Allergy to study drugs (lidocaine or atracurium).
3. Subjects with co-existing disease states that could necessitate a diversion :from the
planned anesthetic.
4. Subjects who are known or suspected to be pregnant.

5. Subjects who are non-ambulatory, bed-ridden, and/or wheelchair bound.
6. Any subject who does not have access to a telephone, thus preventing postoperative follow-up contact.
7. Subjects who receive narcotic reversals.
8. Refusal to participate in the study.
9. Subjects having any condition that would be contraindicated by the administration
of any drug or procedure outlined in this study.
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10. Subject or family history of malignant hyperthermia.
11. Subjects with known pseudocholinesterase disorder.
12. Any subjects not able to give full voluntary and informed consent.
Study Limitations

The following conditions limit the conclusions that were drawn upon completion
of this study:
1. The review of literature may not be wholly reflective of reality.
2. The individual subject variability in response to the prescribed anesthetic
regimen.
3. The possibility exists that multiple sources of error surrounding measurements
of subject's fasciculation may skew the results. In the current study, the
sources of measurement error had been minimized by the use of a single
observer for the measurement of fasciculation, and a measurement tool that
has been used by other researchers measuring fasciculation.
4. The small population to be studied may not be large enough to make
generalizations to larger population regarding the use of lidocaine alone,
lidocaine with atracurium or atracurium alone and their role in preventing
fasciculations.
5. No control group is being studied for treatment comparison.
6. The OAFS scale being utilized to measure fasciculations has not undergone
extensive psychometric testing for validity or reliability.
7. The influence of the amount and type of additional medications prescribed by
the subject's surgeon during the pre-operative period.
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8. The amount and type of medication currently be utilized by the subject at the
time of surgery.
Data Analysis

Comparison of the mean scores of the three study groups would traditionally have
been performed by analysis of variance (ANOVA) utilizing parametric testing. However,
this statistical application would have required a specific distribution of the mean and
variance. Testing of the OAFS lies within a gray area and, as such, a distribution could
not be assumed. Therefore, a nonparametric one-way ANOVA with post-hoc analysis
was employed. Specifically, the Kruskal-Wallis, a test for two or more independent
samples, and the Bonferroni test utilizing a significance level of p<=0.05 was emplored.
The Kruskal-Wallis test calculates results based on the sums of the ranks of the
combined groups in the OAFS. For example, the scores for each variable (0,1 ,2,3) were
ranked, and the mean ranks for the variables were compared. If a significant difference
had been found (p<=0.05), a post-hoc analysis utilizing the Bonferroni method would
have been employed to identify where the difference would have laid. Depending on the
gender make-up of the study population, a backwards regression test may have been used
to analyze any relationships between gender and fasciculations, so as to identify which
variable influenced the dependent variable the most. Because this method is more
sensitive in small comparisons, it was to be utilized in this study.
Protocol

1 . After informed consent is obtained by one of the investigators, the subject will be
transported to the operating room and positioned on the operating table
appropriately for the surgical procedure to be performed.
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2. Standard monitoring will be in utilized (Appendix C).
3 . Subject will be pre-oxygenated with 1 00% inspired oxygen fo r two minutes or
five-vital capacity breathes.
4. The experimental pretreatment drug will be given with fentanyl 1 .5 mcg/kg.
This dose of fentanyl is given to blunt stimulation from laryngoscopy and has not
been demonstrated to affect myalgias in previous investigations.
5 . Five minutes after the administration of the pretreatment drug an appropriate
induction dose of propofol (2-2.5 mg/kg IV) will be given for the induction of
general anesthesia.
6. After the induction dose of propofol is administered, and the subject loses their lid
reflex, l .5mg/kg of SCh will be administered intravenously. The subject will be
observed· for evidence of fasciculations. The fasciculation observer will be the
same for. all subjects, and this individual who is trained and qualified as a research
assistant, but is not one of the researchers will classify the severity of any
witnessed fasciculation based on the 0-3 Observers Assessment of Fasciculation
Scale (OAFS), (Appendix A).
7. After complete muscle relaxation is verified by 0/4 twitches following ulnar nerve
stimulation via cutaneous electrodes, tracheal intubation will be performed and
endotracheal tube placement will be verified by standard methods.
8. Anesthesia will be maintained with oxygen, and air or nitrous oxide, and by
titrating sevoflurane 0.6%-5% to the individuals subject's homodynamic stability
and necessary surgical level of anesthesia corresponding to the degree of surgical
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intervention required. The Bispectral Index (BIS®) monitor will be utilized as an
adjunctive monitor to help assess the patient's level of anesthetic depth.
9. If the subject's blood pressure and heart rate fluctuates (increases or decreases)
greater then 20% of their base line levels (Appendix D), then vasodilators,
vasopressors, inotropes, or chronotropes will be administered as appropriate for
the situation. If the subject fails to respond, they will be eliminated from this
study, their data will not be utilized for analysis, and all further appropriate
treatment necessary for the situation will be instituted.
1 0. The following drugs will be administered as their need arises: narcotics (fentanyl
2-1 0 mcg/kg), nondepolarizing muscle relaxants, antiemetics, steroids, antibiotics,
vasoactive drugs, and muscle relaxant reversals. These medications are not part of
the study protocol, but are routinely employed in the anesthetized patient. (See
Appendix H for this study's formulary, doses and adverse effects of drugs).
1 1 . After completion of the surgery, anesthesia will be discontinued. The subject will
administered 1 00% oxygen, and will be extubated when extubation criteria are
met (Appendix E). Following extubation, the subject will be taken to the post
anesthesia recovery room.
Instrumentation

The Observers Asses�ment of Fasciculation Scale (OAFS) was the tool used to
gauge fasciculations in study subjects following SCh administration. The OAFS is a
four-point ordinal scale that measures the severity of fasciculations from zero to three,
where [O] indicates no fasciculations observed, [1 ] indicates mild fasciculations observed,
[2] indicates moderate fasciculations observed, [3] indicates severe, vigorous
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fasciculations observed (see Appendix A). Although the OAFS has been used in several
previous studies of similar nature and scope as the current one, this scale has no proven
validity or reliability. However, a version of this tool has been widely used by numerous
authors to accurately measure fasciculation after SCh administration in studies of similar
scope and intent as the current one (Harvey, Roland, Bailey, Tomlin, & Williams, 1 998;
Sosis, Broad, Larijani, & Marr, 1 987; Joshi, Hailey, Cross, Thompson-Bell, & Whitten,
1999; Marr & Sosis, 1 989). These authors have published their results in a vat:iety of
respected and refereed scientific medical journals including: The Journal ofthe American
Association ofNurse Anesthetists, Anesthesia and Analgesia, and The Journal of Clinical
Anesthesia. Consequently, since no better or alternate tool existed which had a proven

higher index of validity or reliability, this author chose to utilize this specific tool (the
OAFS) in the study. The goal of using this tool was to measure the occurrence and
severity of fasciculation following SCh administration subsequent to the administration
of lidocaine, atracurium, or lidocaine and atracurium in combination. Since it was
important to maintain consistency and provide reliable measurement during subject
fasciculation, observer consistency was to be maintained by utilizing the same individual
to judge and record the occurrence of fasciculations of all subjects using the OAFS on
data collection sheet (see appendix F).
Protection ofHuman Subjects

All guidelines of the University of Tennessee Medical Center and The University
of Tennessee-Knoxville Institutional Review Boards were adhered to in order to make
certain that consideration and safety for subjects were met. No data collection occurred
until approval was obtained from the Institutional Review Board (IRB) of the University
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of Tennessee Medical Center and the University of Tennessee, Knoxville. As per
requirement of the clinical site IRB, no identifying information was placed on the master
subject data collection list, thus serving to protect and maintain subject anonymity. The
master subject list and completed survey instruments remained under lock and key by the
principle investigator (IRB approval, Appendix, J).
Each subject was read a script that outlines the conditions of consent to
participate. Informed consent was indicated by the subject's signed, witnessed agreement
to randomly receive one of the three medication protocols and agreement to allow the
observation of fasciculation to be measured and recorded on the OAFS by the
independent observer. The use of this tool was approved by the IRB of both University
of Tennessee Medical Center and the University of Tennessee, Knoxville. Subjects were
made aware that they could withdraw from this study at any time without jeopardizing
their care. The potential risk to subjects was minimal, if any. There were no additional
identified or postulated physical, psychological, social, legal, or other risks to the subjects
participating in this study when compared to nonparticipating patients undergoing
routinely accepted anesthesia care for similar procedures. No drug or procedure included
for use in this study was beyond the accepted scope of the current accepted anesthesia
standard of care. In similar fashion, no drugs or procedures were utilized in any manner
in this study that were not within the realm of accepted anesthesia practice. The only
conceivable increased risk identified by the researchers for subjects enrolled in this study
was that a subject might potentially be able to identify some portion of their data if
contained in published studies. Given that all information for the current study was
analyzed and reported as group data, the potential risk to any individual subject is
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extremely small. Even so, the type of data captured in this study was not of a nature that
should cause public embarrassment if revealed. Therefore the risk of injury had been
estimated to be no greater than that encountered in normal everyday anesthesia practice.
This was underscored by the fact that all medications used during this investigation were
approved by the Federal Drug Administration for use in anesthesia for the purpose
intended. No published data from this study will contain information that could be used
to link any subject to the study results. All original materials and data will be maintained
by the principal investigator for a period of five years following completion of the study,
and will then be destroyed. The data obtained through the conduction of this study may
be maintained in a database by the investigator and these data may be utilized by the
same investigator in conjunction with future study, research, and publication.
Prior to the conclusion of data collection, no subjects were identified by any
method other than by sequential numbering on the demographic data sheet, ,and it never
became necessary for the safety of the subject to reveal the blinded information. If such
an instance had occurred (i.e. anaphylaxis or hemodynamic instability), the subject would
have been removed from the study and the double-blinded protocol medication would
have been revealed so as to have provided the most appropriate and prompt intervention
as possible. Since all drugs and patient care interventions were routinely utilized and
administered in the methods and manners for which they were approved, there was less
than minimal potential for subject injury in relation to subject participation in this study.
To date, there were no proven therapeutic alternatives. Many studies have been - .
undertaken to examine this concept. However, these study results have been inconclusive
in yielding definitive results.
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This study was designed to protect subject confidentiality at all phases of
investigation. All demographic data sheets and master subject lists were under the
direct supervision and control of the investigator for the duration of the study. Following
the completion of the study, all data was placed in the anesthesia department in a locked
file cabinet and will be kept for a period of 5 years. After such time (or before if
approved), original data will be destroyed via a paper shredder.
The potential benefits to the subjects of this study, and any subsequent full study,
include a more comfortable recovery time with less additional post-operative discomfort
from SCh-induced myalgias, and a lower likelihood of muscle cell breakdown that could
lead to myoglobinuria, which has been demonstrated to result in renal failure in some
susceptible individuals. There may be fewer returns to the emergency room for
discomfort related to fasciculation, and the potential for a decreased need for post
operative pain medication secondary to cellular damage related to fasciculation. The
prevention of these sequale related to fasciculation could potentially allow subjects to
return earlier to their preoperative baseline status.
All future patients who undergo surgery and receive SCh could be potential
benefactors from the findings of this pilot study. If this pilot study demonstrates that
lidocaine, atracurium, or a combination of both lidocaine and atracurium administered
prior to SCh has superior ability to diminish or prevent fasciculations, future surgical
patients may experience fewer side effects of fasciculations related to SCh
administration.
The results obtained through this study have the potential to improve patient
satisfaction. The most significant anticipated risk was that the pretreatment intervention
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may have helped to prevent or diminish postoperative myalgias. Therefore, it was
estimated that this study could ultimately benefit future patients tremendously by
lowering the negative side effects of SCh, which were reviewed in Chapter II.
Participants in this study did not receive payment or other inducement, in any
form, for their participation. There was no additional cost to the facility for the
conduction of the study or the participation of any subject. Participants in this study had
no additional financial obligations as a result of participation. There were no additional
costs to the research facility. There were no identified financial conflicts of interest.
Prior to the conclusion of data collection, subjects were not identified by any
method other than by sequential numbering on the demographic data sheet and it never
become necessary, for the safety of the subject, to identify them prior to study
completion. If such an instance had occurred (i.e. anaphylaxis or hemodynamic
instability), they would have been removed from the study, and the double-blinded
protocol medication would have be revealed so as to provide the most appropriate and
prompt intervention as possible. Since all drugs and patient care interventions used are
routinely utilized and administered in methods and manners for which they are approved,
there was less than minimal potential for subject injury in relation to subject participation
in this study.

35

CHAPTER IV
Results
Chapter IV presents the results of the data analyses of the research question under
investigation. The primary purpose of this study was to examine and compare the
efficacy of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in
combination as they relate to the incidence and severity of fasciculation in subjects
receiving succinylcholine. The second purpose was to determine the feasibility of
conducting a full study to compare the differential effects of pretreatment with lidocaine,
atracurium, or lidocaine and atracurium in combination as they relate to the incidence and
severity of fasciculation in subjects receiving succinylcholine. A third purpose was to
identify correlations between demographic data and fasciculation in subjects who
received lidocaine, atracurium, or lidocaine and atracurium in combination as they relate
to the incidence and severity of fasciculation in subjects receiving succinylcholine, such
as the relationship between smoking and the occurrence of fasciculations, as well as
differences between gender and fasciculations that could hold clinical significance.
These purposes were guided by the following research questions: Will there be any
difference in the observed severity of fasciculation in subjects receiving SCh who also
receive one of three pharmacological regimens consisting of either lidocaine, atracurium,
or lidocaine and atracurium in combination? The null hypothesis for this study stated that
there would be no difference in the observed severity of fasciculations in surgical patients
who receive SCh who are pretreated with one of three pharmacological regimens
consisting of lidocaine, atracurium, or lidocaine and atracurium in combination? The
data obtained as a result of the implementation of this investigation were gathered by the
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utilization of the Observers Assessment of Fasciculation Scale (OAFS) as discussed in
Chapter III.
Subsequent to obtaining IRB approval from The University of Tennessee,
Knoxville and The University of Tennessee Medical Center at Knoxville, the OAFS was
implemented following subject consent to identify answers to the research question. The
research study was initiated in June 2003, and data collection was completed in August
2003. Although the data set for this pilot study contained an inadequate number of
subjects to allow for generalizations of statistical significance (n=14), several
interesting observations were noted that hold clinical significance, and will be discussed
in Chapter V.
Fifteen subjects, who met the inclusion criteria, were approached for participation
in this study. After an explanation of the study by the investigator, informed consent
(Appendix G) was obtained from the subjects. The established and approved protocol
was followed without deviation as detailed in the IRB application (Appendix H). Of the
1 5 subjects who gave informed consent, one subject was excluded from data analyses
because of intraoperative changes in surgical procedure that necessitated removal from
study inclusion, leaving 14 subjects for statistical analysis. Five subjects were randomly
assigned to each of the 3 study groups, with 5 subjects included in the atracurium group,
4 subjects assigned to the lidocaine group, and 5 subjects assigned to the
atracurium/lidocaine group. Data analysis was calculated with the statistical software
program Statistical Package for the Social Sciences SPS®. The descriptive characteristics
of the study population are described in the following tables.
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The age distribution by group is broken down in Table 1 .
Three groups were utilized: Group A, Group B, and Group C. Group A received
0.05mg/kg of atracurium, Group B received 1 .5mg/kg of lidocaine, and Group C received
both 0.05mg/kg of atracurium, and 1 .5mg/kg of lidocaine. Twelve subjects were female,
and the remaining two subjects were male. The ASA physical status of subjects was as
follows: Eight ASA class I subjects, and six ASA class II subjects. Table 2 shows the
distribu�ion of ASA and smoking status.
The OAFS is a four-point ordinal tool that allows for ranking of observed
muscular fasciculations on a scale of 0-3 based on their occurrence and severity.

Table 1
Age of Subjects by Study Groups
Group
Atracurium

Lidocaine

Lidocaine and
Atracurium
Population

Mean age

SD

Minim�m age

Maximum. Age ·

40.8

5 .4

32

46

26.5

3.41

22

30

3 1 .2

7.08

21

41

33.2

---

21

46
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Table 2
ASA Status and Smoking Status by Study Group
ASA I

Group
Atracurium

Lidocaine

Lidocaine and
Atracurium

Smokers

ASA II

Nonsmoker

N=3

N=2

N=0

N= S

N=4

N=0

N=0

N=4

N= l

N=4

N=3

N=2

N=Ntimber of Subjects within each category

After calculating the severity and occurrence of fasciculation, it was interesting to note
that no subjects in any group scored greater than 1 on the 4-point OAFS. This
significance of this finding will be discussed later in the Chapter V.
The incidence of smoking and its relevance, if any, to the current study was also
examined. Only 3 subjects out of 14 were smokers. Of the 14 subjects in this pilot study
analyzed, none of subjects in the lidocaine group smoked, 60% of subjects in the
lidocaine/atracurium group smoked, and no subjects in the atracurium were smokers.
When considered as a single cohort, smokers were found to exhibit fasciculations 67% of
the time, while non-smokers were found exhibit signs of fasciculation 36% of the time.
Keep in mind that all three groups had small populations, and that only the combination
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group had subjects that smoked. It would be interesting to see this break down in a study
with larger groups.
The mean fasciculation scores are listed in Table 3. The comparison of the mean
scores (Table 3) of the three study groups regarding the occurrence of fasciculation was
calculated using a nonparametric one-way ANOVA, see Table 4. This test yielded no
statistical significance regarding the incidence and severity of fasciculations, P-value of
0.627.
In an Analysis of Variance (ANOVA), the measurement of distance between
individual distributions is expressed as an F value. An F of one would indicate that the
null hypothesis is true for this study, an F value of 0.486 was determined. The null
hypothesis for this study stated that there would be no difference in the observed severity

Table 3
Fasciculation: Study Group Means
Mean

Standard
Deviation

Nvalue

0.54

5

Atrqcurium

0.60

Lidocaine

0.25

0.50

4

Combination 0.40

0.55

5
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Table 4
ANOVA: Comparison of Study Group Means
Sum of squares

Df

Mean square

F

Significance

Between Groups

.279

2

0. 1 39

0.486

NS-0.627

Within Groups

3 . 1 50

11

0.286

3.429

13

Total

* = Significant difference at the a. = 0.05 level
NS = Not Significant
Df=degrees of freedom
of fasciculations in surgical patients who receive SCh who are pretreated with one of
three pharmacological regimens consisting of either lidocaine, atracurium, or lidocaine
and atracurium in combination? In spite of an F of 0.486, all groups exhibited to be
effective in decreasing fasciculations, with no group having a score higher then one on
the OAFS.
The significance of this statistical finding was that when viewing all subjects
together, they appeared to be more homogeneous than when they were viewed in groups.
The F value for this study was a typical indicator of a highly non-significant
result. Since no statistical significance was found, no post-hoc analysis was performed.
In addition to the one-way ANOVA, a cross tabulation (Table 5), was run comparing the
occurrence of fasciculation among all 3 study groups. Forty percent of subjects in the
atracurium group exhibited no signs of fasciculation, which equated to a score of zero on
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Table 5
Cross Tabulation of the Occurrence of Fasciculation Within Groups
Group

Atracurium

Lidocaine

Atracurium
and
Lidocaine

Total

Fasciculation

Count

Total

0.00

1 .00

2

3

5

% within group

40.0%

60.0%

1 00.0%

% within Fasciculation

25.0%

50.0%

35 .7%

% of Total

14.3%

2 1 .4%

35.7%

3

1

4

% within group

75.0%

25.0%

1 00.0%

% within Fasciculation

37.5%

1 6.7%

28.6%

% of Total

2 1 .4%

7. 1 %

28 .6%

3

2

5

% within group

60.0%

40.0%

1 00.0%

% within Fasciculation

37.5%

33.3%

35.7%

% of Total

21 .4%

14.3%

35 .7%

8

6

14

% within group

57. 1%

42.9%

100.0%

% within Fasciculation

1 00.0%

100.0%

1 00.0%

% of Total

57. 1%

42.9%

1 00.0%
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the OAFS. Seventy-five percent of subjects assigned to the lidocaine group scored a zero
on the OAFS. The lidocaine/atracurium group had 60% of subjects score zero. As
previously mentioned, these data supported the fact that no statistical significance existed
when all three groups were compared. Since such a small population was used for this
pilot study (N=l 4), it was an expected finding that statistical tests would not identify any
statistical significance between lidocaine, atracurium, or lidocaine and atracurium in
combination, and as expected, none was found (P=. 627). However, when looking at the
three groups individually, there were differences between groups regarding the
occurrence of fasciculations. This author feels that the differences found among the
groups establishes clinical significance and warrants a larger-full scale study to further
investigate the validity of the different findings among treatment with lidocaine,
atracurium, or lidocaine and atracurium in combination. In addition there were no
subjects in any group to score greater then 1 on the OAFS. This too is clinically
significant if indeed it was the treatment drugs that kept all OAFS scores at one. All
investigations that used the OAFS and looked at NDMRs and lidocaine
showed some scores greater then 1 . Perhaps the group size played a role in this pilot
study's findings.
Following the evaluation of the data with the (one-way ANOVA), a Kruskal
Wallis test, (Table 6), was utilized to compare the ranks of fasciculation score among the
group and to verify the results computed by the ANOVA. Among all subjects that
fasciculated, the maximum observed OAFS score was one. Therefore, among all groups,
no subjects scored greater than one on the OAFS, which indicates that all treatments may
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Table 6
Kruskal Wallis Test
(a) Mean R£l!llcs of Study Groups
Group
Fasciculation
Atracurium
Lidocaine
Atracurium
and Lidocaine
Total

N

Mean Rank

5

8.70

4

6.25

5

7.30

14

(b) Test Statistics o f Group Means
Fasciculation
Chi-Square

1 .056

Df
0.590
Asymp. Sig
=
* Significant difference at the a = 0.05 level
NS = Not Significant
Df=degrees of freedom
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have been effective in attenuating the severity of fasciculations. This test calculated a P
value of 0.590, which also indicated statistical insignificance.
Summary
The answers to the research question was as follows: All pretreatment results in
no subject scoring greater then a score of one on the OAFS. Clinically, 1.5mg/kg of
lidocaine appeared to be most effective at preventing the occurrence of fasciculations
75% of the time. Forty percent of subjects receiving 0.05mg/kg of atracurium did not
fasciculate. When lidocaine and atracurium were given in combination sixty percent of
subjects failed to fasciculate.
This study found that it would be feasible to perform a full-scale study comparing
nondepolarizing blocking agents and lidocaine with their relation to the attenuation of
fasciculation when SCh is utilized as a component of a general anesthetic. There are
enough subjects available to perform a larger study, if time is not a consideration.
Because of the low risks associated with this type of study, subjects are willing to
participate, only one subject failed to give informed consent when approached. All three
groups were effective at reducing the severity of fasciculations equally, with no group
having any subjects score higher then 1 on the OAFS. Lidocaine followed by the
combination of atracurium and lidocaine, and atracurium by itself showed to be an
effective pretreatment for preventing fasciculations. Smokers exhibited fasciculations
more often then nonsmokers when given lidocaine alone and when combined with
atracurium. No smokers were assigned to the atracurium group for comparison.
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CHAPTER V

Conclusions and Discussion
The conclusions and implications of the findings are discussed in this chapter.
Comparison ofstudy results with current literature and recommendations for future
research are al�o addressed. The purpose was to examine and compare the efficacy of
pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as
they relate to the incidence and severity of fasciculation in subjects receiving
succinylcholine. A second purpose was to determine the feasibility of conducting a full
study to compare the differential effects of pretreatment with lidocaine, atracurium, or
lidocaine and atracurium in combination as they relate to the incidence and severity of
fasciculation in subjects receiving succinylcholine. A third purpose was to identify
correlations between demographic data and fasciculation in subjects who received
lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the
incidence and severity of fasciculation in subjects receiving succinylcholine.
Currently, there is much research available by a multitude of authors who have
studied these classes of drugs. However, the current findings and science regarding their
uses as defasciculating agents preceding the administration of a depolarizing muscle
relaxant drug fail to identify a best practices regimen to attenuate· succinylcholine
associated fasciculations.
Following IRB approval and randomization of treatment drugs by the operating
room pharmacy, subj ects were identified as described in Chapter III. Identification of
potential subjects meeting study criteria initiated chart reviews to confirm
appropriateness for inclusion in the study. Those individuals determined to be acceptable
47

for inclusion were approached to elicit their interest in participation. If interested,
informed consent was obtained; the pharmacy was provided the subject's name, weight,
BMI, and height for appropriate calculation and preparation of study drugs for dispensing
in a randomized manner per standardized study protocol.
Discussion
The principle purpose of this pilot study was to determine the feasibility of
conducting a full-study to compare the differential effects of pretreatment with lidocaine,
atracurium, or lidocaine and atracurium in combination as they relate to the incidence and
severity of fasciculation in subjects receiving SCh. This study followed the current
design that had been used by previous investigators. This pilot study was a prospective,
double blinded, randomized study of 15 ASA Physical Status I and II class subjects who
underwent general endotracheal anesthesia for laparoscopic surgery. Subjects were
randomly assigned to one of three groups: one group being administered atracurium
alone, a second group of subjects receiving lidocaine alone, and a third group who
received both atracurium and lidocaine.
Data analysis was conducted utilizing SPSS statistical software. Subjects were
observed for evidence of fasciculation and severity scored based on the OAFS. The
mean scores of each group was compared utilizing a one-way ANOVA to detect
interaction effects between variables, without statistical significance being found.
It was determined that the study design was appropriate and that it could be
easily conducted with a larger population, future study of this topic could be readily
undertaken by utilizing a similar research design. It was also believed that the results of
this pilot study justifies a larger scale investigation, which would focus on the
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administration ofNDMR and lidocaine to attenuate fasciculations associated with the use
of succinylcholine. This belief is based on the relative ease of subject access and the
considerable degree ofclinical significance found as a result of the conduction of the
study.
The secondary purpose of this pilot study was to examine and compare the
efficacy of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in
combination as they relate to the incidence and severity of fasciculation in subjects
receiving succinylcholine. With this in mind, the analysis of the data sets examining the
results of this pilot study investigation demonstrated that, among the subjects treated with
l .5mg/kg of lidocaine alone (n=4), 75% of subjects showed no signs of fasciculation.
When looking at the subjects that received 0.05mg/kg of atracurium alone (n=5), 40% did
not fasciculate. Sixty percent of subjects (n=5) that received both l .5mg/kg of lidocaine,
and 0.05mg/kg of atracurium did not fasciculate.
When comparing these results with those found in the extant literature, the results
varied as anticipated with a small population. Martin et al ( 1 998) found that 65 % of
subjects failed to fasciculate when smaller doses of atracurium (0.02mg/kg vs. 0.05mg/kg
were used over a shorter time interval (3-min. vs. 5-min). At the same dose of atracurium
utilized in this pilot study, 0.05mg/kg, Hochhalter (1 996) found that among 26 subjects
receiving atracurium 73% showed no fasciculations, and among 20 subjects receiving
0.05mg/kg of atracurium, Raman & San, (1 997) found 60% of subjects failed to exhibit
signs of fasciculations. This study' found 40% of subjects in the atracurium group
exhibited signs of fasciculations. This is close to the findings of Raman and San (1997).
It is postulated that had more subjects been studied, as in a full study, the results would
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have demonstrated that greater than 40% of subjects receiving lidocaine may not have
fasciculated. The investigation performed by Raman & San in 1997 was very similar to
this author's study. Even though they used the same drugs, same drug doses and groups,
they did, however, have a larger population. Raman & San found 60% of subjects
receiving atracurium alone and as follows for lidocaine and the combination group.
Twenty subjects received l .5mg/kg of lidocaine alone and only 15% did not fasciculate,
and 70% of their combination group did not exhibit signs of fasciculation. The findings
�f this pilot study showed lidocaine to be much more effective at preventing fasciculation
then did that of Raman and San, (75% vs. 15%) and although this is not a statistically
significant finding to be generalized beyond these fifteen subjects, it is of potential
clinical significance, and reinforces the importance for further investigation in this area of
the science.
A third purpose of this study was to identify correlations between demographic
data and fasciculation in subjects who received lidocaine, atracurium, or lidocaine and
atracurium in combination as they relate to the incidence and severity of fasciculation in
subj ects receiving succinylcholine. To that end, it was interesting to note the influence of
smoking on fasciculation. Results would appear to suggest that this subpopulation of
subjects tended to fasciculate more often than non-smokers, even when pretreated to
attenuate fasciculations that occur after succinylcholine administration. Because this
study subpopulation was so small, and the distribution of smokers among the groups was
uneven, it is not possible to make any generalizations or suggest that smokers may
fasciculate more than nonsmokers. This observation, however, makes for interesting
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consideration, and the possibility of correlation should be explored further in future
studies.
Confounding Variables

There were many factors that contributed to the completion of this study. The
willingness of the pharmacy, operating room staff, anesthesia providers, and surgeons to
allow time for subject consent, preparation of study drugs, and administration of the
study protocol all played a vital role and helped facilitate the investigation. These
individuals took time out of their normal routine to allow for informed consent to be
obtained, study drugs to be properly prepared for administration, and time for individual
anesthesia providers to explain the study protocol to any other anesthesia providers
recruited to assist with data collection.
Although an abundance of laproscopic procedures were performed at this
investigation site, many potential subjects had to be excluded from inclusion in the study
because their BMI was too high, frequently being greater then 30. Since all drug dosages
were based on subject weight, changing the inclusion criteria to allow the inclusion of
patients with a higher BMI should be considered in future studies.
While there were many people and events that aided the completion of this study,
there were a few unforesee? matters that hampered the maximally efficient completion of
this study. Due to the many responsibilities of the operating room pharmacist and the
ever-increasing pressure for rapid tum over between surgical cases, there were times
when, following the securing of informed consent from a qualified study subject, there
simply was not enough time to get the required information to the pharmacy, contact the
pharmacist and have the drugs drawn up in time for the subject's case.
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The scarcity of extra personnel in today's busy surgical environments means that
everyone is usually working at maximum efficiency and may not have the resources of
time and labor to facilitate a research study. Thus, this author suggests allowing a longer
time frame for data collection and reinforcing the importance of the chosen observer
being present for every subject. If the person will not be available, this needs to be
accepted as a limitation up front. The anesthesia department's researcher was chosen to
be the single fasciculation observer. The independent researcher, however, has many
responsibilities and so was not always available when subject observation was needed.
Because this study was a pilot study with fifteen subjects, the findings were not
expected to be generalizable to larger population. The intention of this investigation _was
to determine the feasibility of a larger future study regarding the use of lidocaine alone,··
atracurium alone and lidocaine in combination with atracurium and their role in
preventing fasciculations. While impossible to eliminate all variables in human subjects
research, the influence of the identified limitations and confounding variables could have
been greatly reduced with a larger sample sizes. In addition, there were some unforeseen
aspects of this investigation that were problematic for the researchers. Because of the
small sample size, unequal division of subjects among study group occurred. . Of the
fifteen subjects chosen one had to be excluded, leaving the lidocaine group with one
subject less than the others. Because only fifteen subjects were randomized by the
operating room pharmacy, finding and using a sixteenth subject would have upset the
randomization. Excluding subjects from analysis is a potential problem and there are few
things that could have been done other than having a larger population from the
beginning. However, since this was a pilot study and statistical significance was not a
52

goal or an expected finding of this research study, this situation did not prove to be
problematic.
When examining the unequal gender distribution that occurred in this pilot study,
it is important to remember that at this facility it appears that more women tend to
undergo laproscopic surgeries than do men. The population size of 15 left far fewer men
than women for analysis. This situation could be overcome in future studies with a larger
population or by using a type of surgery where there would be a more equal gender
distribution, such as cystoscopies for stent placement. When looking at smokers, the
distribution was also skewed among the groups because of the small population and this
must be accepted as a limitation.
The operating room pharmacist was not always available to prepare the study
drugs. This is beyond the author's control because the pharmacists have other
responsibilities and, since this was not a funded study, they could not be expected to put
their duties aside whenever a subject was enrolled. Multiple observers had to be utilized
to judge fasciculation with the OAFS. Whenever multiple observers are utilized, there is
always the potential for variability among observation, even when all observers were
explained the OAFS. This, unfortunately, has a large effect ·on the validity of this study' s
results. In the future, investigators must have a dedicated observer or accept the
consequence of possibly invalid findings.
No control group was utilized because it is known that there is an association
between fasciculations and the administration of succinylcholine. However there may
have been a statistical significance between the treatment groups and a control group that
did not receive a defasciculator. Also a control group was not utilized because of the
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association of myalgias with fasciculation and subjects may have been less willing to
participate if a control group was utilized. It is postulated that a control group should be
utilized in future studies for comparison and to determine if statistical significance
between treatment groups and a control may exist.
Because different medications have different onset times, a five-minute interval
was chosen to ensure onset of treatment medications. When inducing a general
anesthetic, however, five minutes is a long time to w�it. This leaves the chance that
anesthesia providers who participated in this study may not have truly waited the five
minutes. This possibility exists and should be considered. The importance of following
study protocols should be emphasized for all future researchers.
Findings ·

The most surprising and completely unexpected finding of this pilot study was
that 75% of subjects receiving lidocaine did not fasciculate thus, lidocaine administered
alone was demonstrated to be the most effective agent for preventing fasciculations when
compared to atracurium alone, (40% ), and to atracurium in combination with lidocaine,
(60%). Melnick, Chalasani, Nonita, Uy, Phitayakom, Mallett, and Rudy (1 987) found
lidocaine to be no more effective then normal saline at reducing fasciculations. All the
current literature reviewed in preparation for this thesis showed lidocaine to be the least
effective for attenuating fasciculations following succinylcholine administration when
compared to atracurium and other nondepoloraizing muscle relaxants such as d
tubocurarine. The current literature looking at lidocaine alone is minimal because the
existing studies show NDMRs alone and in combination with lidocaine to be more
effective and this appears to be where the current focus is. Whether or not the results of
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this study will be supported with data from future investigations will have to be
determined in subsequent studies. This factor, in complete isolation, provides support for
continuing the collection of data on this subject and to seek to establish statistical
significance. To do so would be to offer the profession a tremendous amount of
knowledge capable of altering practice for the betterment of patients. Lidocaine is
economically far superior to all commercially available muscle relaxants in use at this
time for the purpose of preventing fasciculations in patients receiving depolarizing
neuromuscular blockade as a component of their general anesthetic. The use of lidocaine
for defasciculation represents the expenditure of pennies for each patient in contrast to
dollars to utilize a nondepolarizing agent. In addition, the large margin of safety and
dramatically lower potential for negative outcome when lidocaine is utilized, in
comparison to any nondepolarizing neuromuscular blocking agent, further supports the
need to validate these clinical significant findings with larger subject sample sizes.
Sixty percent of the subjects in this pilot study who received lidocaine along with
atracurium did not fasciculate (n=5). This author expected that this finding would have
been higher. Melnick, Chalasani, Nonita, Uy, Phitayakom, Mallett, and Rudy ( 1 987)
found the combination of dTc and lidocaine to be superior to both dTc or lidocaine whe�
utilized individually for attenuating fasciculations. When comparing the results of
Raman and San ( 1 997) and the results of this author' s pilot study, in regard to the
similarity of the combination of lidocaine with atracurium, the observed results were
similar. Both studies used l .5mg/kg of lidocaine and 0.05mg/kg of atracurium. Seventy
percent of the subjects in Raman and San's study who received both did not fasciculate
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and 60% of the subjects in this pilot study did not fasciculate. This study' s findings were
similar and show that this finding has some validity and should be further investigated.
Recommendations for Future Study/Investigation
Although the current science regarding the relationship between nondepoloraizing
muscle relaxants and the local anesthetics is large and many aspects have been studied,
no specific drug or combination of drugs is spelled out to be the best for the prevention of
fasciculations. Every study is going to have its limitations. It is impossible to have a
perfect study design. Unexpected events are going to occur and they may result in
accidental findings, or incorrect findings that, if followed, can result in injury. It is
important for all researchers to relay information they found, problems they have
incurred, and to offer suggestions to other researchers. This is important because it helps
future studies to be designed and carried out with minimal limitations, and problems. It
also allows practitioners to make.more informed decisions regarding their practice. By
taking into consideration the mistakes and problems others have incurred, more
generalized studies can be designed and implemented. Recommendations for future
studies are as follows, to undertake:
1. Larger studies looking at any relationship between the occurrence of
fasciculations and smoking.
2. Larger studies looking at the role gender may or may not play on
fasciculations.
3. Larger studies comparing lidocaine, atracurium, and their combination and
their ability to attenuate fasciculations.
4. Studies including a control group as well as the treatment groups.
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5. Studies having one observer for _all subjects.
Conclusions

In summary, this pilot study was conducted to:
1). Establish the feasibility of performing a full-scale study to investigate nondepolarizing
neuromuscular blocking agents and their relation to the attenuation of fasciculation when
SCh is utilized as a component of a general anesthetic.
2). Appraise the difference in observed fascicul':1,tion when lidocaine alone, atracurium
alone, or lidocaine and atracurium in combination are administered as a defasciculating
agent prior to SCh.
3). Identify and uncover statistical trends that occurred within the study population that
may hold clinical significance without statistical significance, due to the low number of
subjects ·studied.
The results were not statistically significant or able to be generalized to larger
populations. However data analysis demonstrated potential clinical significance, as
evidenced by low OAFS scores and a greater number of subjects, than not failing to
fasciculate to any measurable or observable degree. This finding warrants further
investigation with larger populations. The combination of l .5mg/kg of lidocaine in
combination with 0.05mg/kg of atracurium was found to have similar effects preve1:1ting
fasciculation as other studies/authors have found. No subject that was observed to
fasciculate in any of the three groups received a OAFS score greater then one. Signs of
fasciculation could have been missed by any of the many observers leading to inaccurate . ·
fasciculation recording. It seems reasonable to assume that the variable of smoking may
have played a role in fasciculation. However, generalizations cannot be made from a
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population of 14. Perhaps if future investigators continue to carryout thorough literature
reviews and continue to consider the mistakes and suggestions of others when designing
future studies, future knowledge obtained from research regarding the use ofNDMR and
lidocaine in attenuating fasciculation will allow anesthesia providers to administer a best
single drug or combination of drugs and prevent fasciculations and their sometimes life
threatening complications.
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Appendix A
Observers Assessment of Fasciculation Scale
(OAFS)
[0] No fasciculations witnessed

[ 1] Mild, fine fasciculations of the eyes, face, neck or fingers without limb movement

[2] Moderate fasciculations of greater intensity than mild that occurred at more than two
sites or that produced limb movement

[3] Severe vigorous, sustained and widespread fasciculations possibly requiring forceful
retention.
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Appendix B
ASA Physical Status Classification

http://www.asahq.org/clinicaVphysicalstatus.htm

Class 1- A normal healthy patient
Class 2-A patient with mild systemic disease
Class 3 -A patient with severe systemic disease
Class 4-A patient with severe systemic disease that is a constant threat to life
Class 5-A moribund patient who is not expected to survive without the operation
Class 6- A declared brain-dead patient whose organs are being removed for donor
purposes
Class E- If the procedure is an emergency, the physical status is followed by an "E"
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Appendix C
Standards for Basic Intraoperative Monitoring

Note: Within these standards, "Anesthesia" is defined as all types of anesthesia care
unless otherwise specified by the text.
(Approved by House of Delegates on October 2 1 , 1 986 and last amended on October 21,
1 9981)
http://www.asahq.org/publicationsandservices/standards/02.html
These standards apply to all anesthesia care although, in emergency circumstances,
appropriate life support measures take precedence. These standards may be exceeded at
any time based on the judgment of the responsible anesthesiologist. They are intended to
encourage quality patient care, but observing them cannot guarantee any specific patient
outcome. They are subject to revision from time to time, as warranted by the evolution of
technology and practice. They apply to all general anesthetics, regional anesthetics and
monitored anesthesia care. This set of standards addresses only the issue of basic
anesthetic monitoring, which is one component of anesthesia care. In certain rare or
unusual circumstances, I ) some of these methods of monitoring may be clinically
impractical, and 2) appropriate use of the described monitoring methods may fail to
detect untoward clinical developments. Brief interruptions of continual# monitoring may
be unavoidable. Under extenuating circumstances, the responsible anesthesiologist may
waive the requirements marked with an asterisk (*); it is recommended that when this is
done, it should be so stated (including the reasons) in a note in the patient's medical
record. These standards are not intended for application to the care of the obstetrical
patient in labor or in the conduct of pain management.
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STANDARD I
Qualified anesthesia personnel shall be present in the room throughout the conduct of all
general anesthetics, regional anesthetics and monitored anesthesia care.
OBJECTIVE
Because of the rapid changes in patient status during anesthesia, qualified anesthesia
personnel shall be continuously present to monitor the patient and provide anesthesia
care. In the event there is a direct known hazard, e.g., radiation, to the anesthesia
personnel, which might require intermittent remote observation of the patient, some
provision for monitoring the patient must be made. In the event tha� an emergency
requires the temporary absence of the person primarily responsible for the anesthetic, the
best judgment of the anesthesiologist will be exercised in comparing the emergency with
the anesthetized patient's condition and in the selection of the person left responsible for
the anesthetic during the temporary absence.
STANDARD II
During all anesthetics, the patient's oxygenation, ventilation, circulation and temperature
shall be continually evaluated.
OXYGENATION
OBJECTIVE
To ensure adequate oxygen concentration in the inspired gas and the blood during all
anesthetics.
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METHODS
Inspired gas: During every administration of general anesthesia using an
anesthesia machine, the concentration of oxygen in the patient breathing system shall be
measured by an oxygen analyzer with a low oxygen concentration limit alann in use.*
Blood <>.?C:ygenation: During all anesthetics, a quantitative method of assessing
oxygenation s�ch as pulse-oximetry shall be employed.* Adequate illumination and
exposure of the patient are necessary to assess color.*
VENTILATION
OBJECTIVE
To ensure adequate ventilation of the patient during all anesthetics.
METHODS
Every patient receiving general anesthesia shall have the adequacy of ventilation
continually evaluated. Qualitative clinical signs such as chest excursion, observation of
the reservoir breathing bag and auscultation of breath sounds are useful. Continual
monitoring for the presence of expired carbon dioxide shall be performed unless
invalidated by the nature of the patient, procedure or equipment. Quantitative monitoring
of the volume of expired gas is strongly encouraged.*
When.an endotracheal tube or laryngeal mask is inserted, its correct positioning
must be verified by clinical assessment and by identification of carbon dioxide in the
expired gas. Continual end-tidal carbon dioxide analysis, in use from the time of
endotracheal tube/laryngeal mask placement, until extubation/removal or initiating
transfer to a postoperative care location, shall be performed using a quantitative method
such as capnography, capnometry or mass spectroscopy.*
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When ventilation is controlled by a mechanical ventilator, there shall be in
continuous use a device that is capable of detecting disconnection of components of the
breathing system. The device must give an audible signal when its alarm threshold is
exceeded.
During regional anesthesia and monitored anesthesia care, the adequacy of
ventilation shall be evaluated, at least, by continual observation of qualitative clinical
signs.
CIRCULATION
OBJECTIVE
To ensure the adequacy of the patient's circulatory function during all anesthetics.
METHODS
Every patient receiving anesthesia shall have the electrocardiogram continuously
displayed from the beginning of anesthesia until preparing to leave the anesthetizing
location. *
Every patient receiving anesthesia shall have arterial blood pressure and heart rate
determined and evaluated at least every five minutes.*
Every patient receiving general anesthesia shall have, in addition to the above,
circulatory function continually evaluated by at least one of the following: palpation of a
pulse, auscultation of heart sounds, monitoring of a tracing of intra-arterial pressure,
ultrasound peripheral pulse monitoring, or pulse plethysmography or oximetry.
BODY TEMPERATURE
OBJECTIVE
To aid in the maintenance of appropriate body temperature during all anesthetics.
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METHODS
Every patient receiving anesthesia shall have temperature monitored when clinically
significant changes in body temperature are intended, anticipated or suspected.
#Note that "continual" is defined as "repeated regularly and frequently in steady rapid
succession" whereas "continuous" means "prolonged without any interruption at any
time."

. 77

Appendix D
Acceptable Hemodynamic Monitoring Parameters

Heart rate: +/- 20% of baseline
Blood Pressure: +/- 20% of baseline
Oxygen S�turation: 95% or above
Temperature: 35.6 C (96.0) - 37.8 C (1 00.0 F)
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Appendix E
Extubation Criteria
(1)

Train of four i s 4/4 without fade, and a positive sustained tetanus

(2)

Spontaneous respirations of >8, with a tidal volume of>250

(3)

Negative Inspiratory pressure (NIP) of - 1 0

(4 )

Eye opening to voice, or purposeful movement
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Appendix F
Demographic Data Sheet and Master Subject List
Name Phone #
Subject #
Physical Status- I or II
Wt. in kg
Ht. in inches
Gender Smoking hx/# of yrs
Pre-op NSAID NARC
Observers Assessment of Fasciculation Scale
(OAFS)

[O] No fasciculations witnessed

[ 1 ] Mild, fine fasciculations of the eyes, face, neck or fingers without limb movement

[2] Moderate fasciculations of greater intensity than mild that occurred at more than two
sites or that produced limb movement

[3] Severe vigorous, sustained and widespread fasciculations possibly requiring forceful
retention.
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Appendix G
Informed Consent
A Comparison of the Differential Effects of Atracurium and/or Lidocaine on
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia
Investigators
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA

Informed Consent
The study in which you are asked to participate has the goal of reducing muscle twitching
and muscular soreness after surgery, which can occur with succinylcholine
administration. This is a topic that is :frequently studied. Many scientists feel that the
muscle soreness some people experience after surgery is related to the muscle twitching
occurring with succinylcholine administration. You are being asked to participate
because you are in a group of patients who frequently have muscle soreness after surgery,
namely, patients receiving succinylcholine for general tracheal anesthesia.
Succinylcholine is a muscle relaxant that allows your anesthesia provider to place a
breathing tube in your windpipe to protect your airway after you are asleep. This tube
allows you to breath the anesthetic gases that will keep you asleep. This is done routinely
for general anesthesia and will be required regardless of your participation in this study.
You should be unaware of this tube placement and should not remember it. All subjects
will be selected from the daily surgical schedule at the University of Tennessee Medical
Center.
This study will examine two anesthetic medications that are routinely used to prevent
muscular twitching and soreness. Neither drug has been proven superior in preventing
muscle twitching or muscular soreness. We are asking permission to do two things
during this study. First, to record any muscular twitching we may observe, and second,
to ask you some simple questions after surgery about whether you are experiencing any
muscular soreness. You will be contacted by phone 24, 48, and 72 hours after your
surgery by one of the investigators. If your surgeon admits you to the hospital, you will
be visited in your room by one of the investigators.
The medications used will consist of a muscle relaxant (atracurium), or local
anesthetic/numbing (lidocaine) medication. Some patients may receive both medications.
These medications will be administered in a double blind method. This means that neither
you nor the anesthesia provider will know which drug was given until the conclusion of
the study. The doses of the medicines, however, will be carefully and safely prepared for
you under the supervision of a licensed pharmacist. You will receive standard and
acceptable doses of all medications, just as you would if you chose not participate in this
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study. They will look the same, and no one except the pharmacist will know what you
received until all the patients have been studied.
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FS 03/03 Patient Initials -- Date
A Comparison of the Differential Effects of Atracurium and/or Lidocaine on
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia
Investigators
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA

You will be assigned a unique number that will be used to identify you and the
information we gather. If something were to happen that required the knowledge of what
drug you received we would use that number to obtain the necessary information. There
may be around 100 patients involved in this study, and it will probably take several
months to gather all the information we need.
Risks Associated with Participation
Since the medications you will receive today are routinely used for anesthetics, there is
essentially no increased risk to you associated with your participation in this study.
However all medications have side effects and could cause adverse reactions. Although
rare, some possible side effects that could occur include nausea, vomiting, sedation,
prolonged muscle weakness, high potassium, increased body temperature, and seizures.
If you experience the common side effects of pain, nausea, or vomiting after your
surgery, standard medications for these conditions will be administered, just as they
would be for anyone else. You are not expected to experience any increased discomfort
as a result of your participation in this study.
All records are kept confidential. As stated earlier you will be assigned a number which
will be used as your identifier, rather than using your name. These records will be kept in
the Anesthesia Office under lock and key for a period of five years from the conclusion
of the study. After five years, they will be destroyed.
Benefits to Participants
The hope is to gain information from this study that may help patients in the future with
their post-surgery recovery. The potential benefits to the subjects may include a more
comfortable recovery time and possibly an earlier return to their pre-surgery level of
function. All future patients who undergo surgery and receive succinylcholine could
potentially benefit from this study. If this study demonstrates that one or the
combination of pretreatment medications has superior ability to diminish or prevent
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muscle twitching and muscular soreness, then future patients may experience less
discomfort after surgery.
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A Comparison of Differential Effects of Atracurium and/or Lidocaine on
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia
Investigators
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA

Alternatives to participation
There is no superior drug or treatment to prevent succinylcholine induced muscle
twitches or muscular soreness.
Confidentiality
Although study results may be published, your confidentiality will be maintained. Your
name or information identifying you will not be released without written permission
unless required by law. Under federal privacy regulations, you have the right to
determine who has access to your personal health information (called "protected health
information" or PHI). PHI collected in this study may include your medical history, the
results of physical exams, lab tests, x-ray exams, and other diagnostic / treatment
procedures, as well as basic demographic information. By signing this consent form, you
are authorizing the researchers at the University of Tennessee Medical Center to have
access to your PHI collected in this study and to receive your PHI from (Jack Chavez
M.D.) , and may.the University of Tennessee Medical Center where you have received
health care. In addition, your PHI may be shared with other persons involved in the
conduct or oversight of this research, including the (FDA) Food and Drug
Administration, the University of Tennessee Medical Center, and the University of
Tennessee Graduate School of Medicine Institutional Review Board. Your PHI will not
be used or disclosed to any other person or entity, except as required by law, or for
authorized oversight of this research study by other regulatory agencies, or for other
research for which the use and disclosure of your PHI has been approved by the IRB .
Your PHI will be used indefinitely. You may cancel this authorization in writing at any
time by contacting the Principal Investigator listed on the first page of the consent form.
If you cancel the authorization, continued use of your PHI is permitted if it was obtained
before the cancellation and its use is necessary in completing the research. However, PHI
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collected after your cancellation may not be used in the study. If you refuse to provide
this authorization, you will not be able to participate in the research study.
If you cancel the authorization, then you will be withdrawn from the study. Finally, the
federal regulations allow you to obtain access to your PHI collected or used in this study.
However, in order to complete the research, your access to this PHI may be temporarily
suspended while the research is in progress. When the study is completed, your right of
access to this information will be reinstated.

3 of 5
FS 3/03 Patient Initials __ Date __
A Comparison of the Differential Effects of Atracurium and/or Lidocaine on
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia
Investigators
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA

Liability
You understand that you are not waiving any legal rights or releasing the hospital or its
agents from liability for negligence. You understand that in the event of physical injury
resulting from research procedures, the University of Tennessee does not have funds
budgeted for compensation either from lost wages or for medical treatment. Therefore,
the University does not provide reimbursements for such injuries.
By signing this form, you indicate that: You have read the description of the above study
and have freely volunteered to participate in it. You have had possible side effects and
adverse reactions explained to you and have had alternative therapies explained. You
have had an opportunity to ask questions of the investigator and have received acceptable
answers. You understand you may . withdraw from this study.at any time and will still
receive standard treatment for your condition.
Payment for Participation
There is no payment in any form to study participants.
Costs of Participation
There are no additional costs to you for participating in this study.
Contact/Questions
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If you have any questions about the nature of this study, or feel that you have had an
adverse reaction, please feel free to contact Jack Chavez, MD at (865-544-9220), Tonya
Campbell (865-544-9220) , or Fred Schrimpe (865-544-9220). If you have any questions
about your rights as a research subject, please call the Institutional Review Board at (865544-978 1 ). Thank you for your consideration.
Consent of Subject
I have read or have had read to me the description of the research study as outlined
above. The investigator or his/her representative has explained the study to me and has
answered all of the questions I have at this time. I have been told of the potential risks,
discomforts, side effects and adverse reactions as well as the possible benefits (if any) of
the study.
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A Comparison of the Differential Effects of Atracurium and/or Lidocaine on
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia

Investigators
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA

I freely volunteer to participate in this study. I understand that I do not have to take part
in this study and that my refusal to participate will involve no penalty or loss of rights too
which I am entitled. I further understand that I am free to later withdraw my consent and
discontinue participation in this study at any time. I understand that refusing to participate
or later withdrawing from the study will not adversely affect my subsequent medical care.
Signature______________Date___
Date___
Investigator Signature
Date___
Witness
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Appendix H
Inclusion and Exclusion Criteria
Inclusion Criteria
6. 18-50 years of age
7. Subjects requiring elective outpatient laproscopic surgery under general
endotracheal anesthesia
8. BMI between 18-30
9. Physical Status I or II
10. Ambulatory patients only
Exclusion Criteria
13. Those patients not meeting the inclusion criteria as detailed.
14. Allergy to study drugs (lidocaine or atracurium).
15. Subjects.with co-existing disease states that could necessitate a diversion from the
planned anesthetic.
16. Subjects who are known to be pregnant.
17. Subjects who are non-ambulatory, bed-ridden, or wheelchair bound.
18. Any subject who does not have access to a telephone, thus preventing postoperative follow-up contact.
19. Subjects who receive narcotic reversals.
20. Refusal to participate in the study.
21. Subjects having any condition that would be contraindicated by the administration
of any drug or procedure outlined in this study.
22. Subject or family history of Malignant Hyperthermia.
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23. Subjects with known pseudocholinesterase disorder.
Any subjects not able to give full voluntary and informed consent.
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Appendix I
Protocol

Study Protocol

12. After informed consent is obtained by one of the investigators, the subject will be
transported to the operating room and positioned on the operating table
appropriately for the surgical procedure to be performed.
13. Standard monitoring will be in utilized (Appendix C).
14. Subject will be pre-oxygenation with 100% inspired oxygen for two minutes or
five-vital capacity breathes.
15. The experimental pretreatment drug will be given with fentanyl 1.5 mcg/kg.
(This dose of fentanyl is given to blunt stimulation from laryngoscopy and has not
been demonstrated to affect myalgias in previous investigations).
16. Five minutes after the administration of the pretreatment drug an appropriate
induction dose of propofol (2-2.5 mg/kg IV) will be given for the induction of
general anesthesia.
17. After the induction dose of propofol is administered, and the subject loses their lid
reflex, 1.5mg/kg of SCh will be administered intravenously. The subject will be
observed for evidence of fasciculations. The fasciculation observer will be the
same for all subjects, and this individual (who is trained and qualified as a
research assistant, but is not one of the researchers) will classify the severity of
any witnessed fasciculation based on the 0-3 Observers Assessment of
Fasciculation Scale (OAFS), (Appendix A).
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1 8. After complete muscle relaxation is verified by 0/4 twitches following ulnar nerve
stimulation via cutaneous electrodes, tracheal intubation will be performed and
endotracheal tube placement will be verified by standard methods.
19. Anesthesia will be maintained with oxygen, and air or nitrous oxide, and by
titrating sevoflurane 0.6%-5% to the individuals subject's homodynamic stability
and necessary a surgical level of anesthesia corresponding to the degree of
surgical intervention required. The Bispectral Index (BIS) monitor will be utilized
as an adjunctive monitor to help assess the patient's level of anesthetic depth.
20. If the subject's blood pressure and heart rate fluctuates (increases or decreases)
greater then 20% of their base line levels (Appendix D), then vasodilators,
vasopressors, inotropes, or chronotropes will be administered as appropriate for
the situation. If the subject fails to respond, they will be eliminated from this
study, their data will not be utilized for analysis, and all further appropriate
treatment necessary for the situation will be instituted.
21 . The following drugs will be administered as their need arises: narcotics (fentanyl
2- 1 0 mcg/kg), nondepolarizing muscle relaxants, antiemetics, steroids, antibiotics,
vasoactive drugs, and muscle relaxant reversals. These medications are not part of
the study protocol, but are routinely employed in the anesthetized patient. (See
Appendix H for this study's formulary, doses and adverse effects of drugs).
After completion of the surgery, anesthesia will be discontinued. The subject will
administered 100% oxygen, and will be extubated when extubation criteria are met
(Appendix E). Following extubation, the subject will be taken to the post-anesthesia
recovery room.
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Appendix J
Internal Review Board Letters of Approval
THE UNIVERSITY OF TENNESSEE

Institutional Review Boarc
Office of Researcl

404 Andy Holt Towe1
Knoxville, Te�essce 3 7996-014(
865-974-346(
Fax: 865-974-280:

May 16, 2003
IRB #: 641_3 B

Title: A Comparison of the Differ�ntial Effects of Atracurium and/or Lidocaine on
Succinylcholine:.induced Fasciculation and Severity of Postoperative Myalgia
- Jack �vez, Co-PI
Anesthesia
UTMCK
1 924 Alcoa Hwy.

Tonya Campbell
Anesthesia
UTMCK .
1 924 Alcoa Hwy.

Fredrick Schrimpe1 Co-PI
Anesthesia
UTMCK
1 9�4 Alcoa Hwy.

John Preston. Advisor
Nursing
1200 Volunteer Blvd.
Campus
At the meeting of the Institutional-Review Board (IRB) held May 1 5, 2003� the above protocol
was reviewed and approved.
.

.

.

This approval for a·period ending one year from the da�e of this letter. Please make timely ·
submission
of renewal or prompt notification
.
� project termination (see item #3 below):

of

Responsibilities of the investigator during the conduct of this project include the following:
1.
2.
3.

Prior approval from the :Committee before insti�ting any changes in the project.
' To retain signed consent forms from subjects for at least three years following
completion of the project.
To submit a·Fonn D .to
month or less intervals.

report changes in the project or to report termination
at 1 2··

The Committee wishes you every success in your research endeavor. This office will send you a
renewal notice (Form R) on the anniversary of your approval date.
Sincerely,
�� .- � � £ -��

fre�on
Compliances
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JHE UNIVERSITY OF TENNESSEE
GRADUATE SCHOOL OF MEDICINE

Office of Institutional Review Board

FWA 2301
1924 Alcoa Highway ·
Knoxville, 1N 37920-6999
(865) 544-9781
FAX (865) 544-9275

March 20, 2003
Jack Chavez, MD
· Department of Anesthesiology
The University of Tennessee Medical Center
1 924 Alcoa Highway
Knoxville, TN 37920 .
RE:

IRS #2233 "A Comparison of the Differential Effects of Atracurium and/or
Lidocaine on Succinylcholine-induced Fasciculation and the Severity of
Postoperative Myalgi�" .

Dear Dr. Chavez,
On March 1 8, 2003, the University of Tennessee Graduate School of Medicine in
Knoxville Institutional Review Board reviewed your above referenceo a pplication. The
Board voted full approval with no abstentions on ttiis protocol including informed
consent form. Your research application will be reviewed ·in one year.
The I nstitutional Review Board · is in compliance with the requirements in Part 50;
56, Subch�pter D.' Part 312 of the 21 Code of Federal Regulations published January 27,
1 981 .
Any alterations in ·the protocol m_ust be . promptJy re·ported to the Institutional
Review Board. In addition, annual reapproval (February 2004) is required by the IRS,
and it is your responsibility as the Principal Investigator to initiate the request'for approval
regardless of the time the study ha� been approved by the sponsoring agency.
You have individual responsibility for reporting to the B_oard in the event of adverse
reactions.

<f---,( r'.-i.- -Sincerely,

#lfA-...0

·

�
- 3/2 03

Joseph E. Fuhr, PhD
Chainnan
Institutional Review Board
JEF: rt

&ceptional medicine. &ceptional peopk.
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VITA
Frederick Christopher Schrimpe was born in East Islip, New York on March 1 3,
1 977. He was one of two children of Frederick and Marie Schrimpe. He completed his
high school education in 1 995 in Knoxville, Tennessee. Mr. Schrimpe graduated with a
BSN from the University of Tennessee, Knoxville in 1 999. He worked in the
Neuro/Respiratory Intensive Care Unit of the University of Tennessee Medical Center
Knoxville as a staff nurse until July of 200 1 . _After working for two and a half years as a
critical care Registered Nurse, he was accepted into the Master's program at the
University of Tennessee, Knoxville. He graduated in December of 2003 with a Master's
of Science in Nursing, Nurse Anesthesia Concentration.
Mr. Schrimpe is a member of Sigma Theta Tau International Honor Society of
Nursing, Gamma Chi Chapter, The TN Association of Nurse Anesthetists, and The
American Association of Nurse Anesthetists. He will begin is career as a nurse
anesthetist in Nashville Tennessee. Mr. Schrimpe is considering pursuing doctoral
studies following a post-master's hiatus.
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